Literature DB >> 34145038

MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma.

Bastian Krenz1, Anneli Gebhardt-Wolf1, Carsten P Ade1, Abdallah Gaballa1, Florian Roehrig2, Emilia Vendelova3, Apoorva Baluapuri4, Ursula Eilers5, Peter Gallant1, Luana D'Artista6, Armin Wiegering1,7, Georg Gasteiger3, Mathias T Rosenfeldt8, Stefan Bauer9, Lars Zender6, Elmar Wolf4, Martin Eilers10.   

Abstract

Deregulated expression of the MYC oncoprotein enables tumor cells to evade immune surveillance, but the mechanisms underlying this surveillance are poorly understood. We show here that endogenous MYC protects pancreatic ductal adenocarcinoma (PDAC) driven by KRASG12D and TP53R172H from eradication by the immune system. Deletion of TANK-binding kinase 1 (TBK1) bypassed the requirement for high MYC expression. TBK1 was active due to the accumulation of double-stranded RNA (dsRNA), which was derived from inverted repetitive elements localized in introns of nuclear genes. Nuclear-derived dsRNA is packaged into extracellular vesicles and subsequently recognized by toll-like receptor 3 (TLR3) to activate TBK1 and downstream MHC class I expression in an autocrine or paracrine manner before being degraded in lysosomes. MYC suppressed loading of dsRNA onto TLR3 and its subsequent degradation via association with MIZ1. Collectively, these findings suggest that MYC and MIZ1 suppress a surveillance pathway that signals perturbances in mRNA processing to the immune system, which facilitates immune evasion in PDAC. SIGNIFICANCE: This study identifies a TBK1-dependent pathway that links dsRNA metabolism to antitumor immunity and shows that suppression of TBK1 is a critical function of MYC in pancreatic ductal adenocarcinoma. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34145038      PMCID: PMC7611539          DOI: 10.1158/0008-5472.CAN-21-1677

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  Target gene-independent functions of MYC oncoproteins.

Authors:  Apoorva Baluapuri; Elmar Wolf; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-18       Impact factor: 94.444

Review 2.  Innate immune pattern recognition: a cell biological perspective.

Authors:  Sky W Brubaker; Kevin S Bonham; Ivan Zanoni; Jonathan C Kagan
Journal:  Annu Rev Immunol       Date:  2015-01-02       Impact factor: 28.527

Review 3.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

4.  PKR Senses Nuclear and Mitochondrial Signals by Interacting with Endogenous Double-Stranded RNAs.

Authors:  Yoosik Kim; Joha Park; Sujin Kim; MinA Kim; Myeong-Gyun Kang; Chulhwan Kwak; Minjeong Kang; Baekgyu Kim; Hyun-Woo Rhee; V Narry Kim
Journal:  Mol Cell       Date:  2018-08-30       Impact factor: 17.970

5.  Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.

Authors:  Michael J Topper; Michelle Vaz; Katherine B Chiappinelli; Christina E DeStefano Shields; Noushin Niknafs; Ray-Whay Chiu Yen; Alyssa Wenzel; Jessica Hicks; Matthew Ballew; Meredith Stone; Phuoc T Tran; Cynthia A Zahnow; Matthew D Hellmann; Valsamo Anagnostou; Pamela L Strissel; Reiner Strick; Victor E Velculescu; Stephen B Baylin
Journal:  Cell       Date:  2017-11-30       Impact factor: 41.582

6.  RIG-I and Other RNA Sensors in Antiviral Immunity.

Authors:  Kwan T Chow; Michael Gale; Yueh-Ming Loo
Journal:  Annu Rev Immunol       Date:  2018-04-26       Impact factor: 32.481

7.  R-loops induce repressive chromatin marks over mammalian gene terminators.

Authors:  Konstantina Skourti-Stathaki; Kinga Kamieniarz-Gdula; Nicholas J Proudfoot
Journal:  Nature       Date:  2014-10-05       Impact factor: 49.962

8.  c-myc down-regulates class I HLA expression in human melanomas.

Authors:  R Versteeg; I A Noordermeer; M Krüse-Wolters; D J Ruiter; P I Schrier
Journal:  EMBO J       Date:  1988-04       Impact factor: 11.598

9.  Intron retention is a robust marker of intertumoral heterogeneity in pancreatic ductal adenocarcinoma.

Authors:  Daniel J Tan; Mithun Mitra; Alec M Chiu; Hilary A Coller
Journal:  NPJ Genom Med       Date:  2020-12-11       Impact factor: 6.083

10.  Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma.

Authors:  Nathiya Muthalagu; Tiziana Monteverde; Ximena Raffo-Iraolagoitia; Robert Wiesheu; Declan Whyte; Ann Hedley; Sarah Laing; Björn Kruspig; Rosanna Upstill-Goddard; Robin Shaw; Sarah Neidler; Curtis Rink; Saadia A Karim; Katarina Gyuraszova; Colin Nixon; William Clark; Andrew V Biankin; Leo M Carlin; Seth B Coffelt; Owen J Sansom; Jennifer P Morton; Daniel J Murphy
Journal:  Cancer Discov       Date:  2020-03-21       Impact factor: 39.397

View more
  2 in total

Review 1.  Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.

Authors:  Adithya Balasubramanian; Thomas John; Marie-Liesse Asselin-Labat
Journal:  Biochem Soc Trans       Date:  2022-04-29       Impact factor: 4.919

2.  Epigenetic state determines inflammatory sensing in neuroblastoma.

Authors:  Adam J Wolpaw; Liron D Grossmann; Jessica L Dessau; May M Dong; Bailey J Aaron; Patricia A Brafford; Darya Volgina; Guillem Pascual-Pasto; Alba Rodriguez-Garcia; Yasin Uzun; Marie Arsenian-Henriksson; Daniel J Powell; Kristopher R Bosse; Andrew Kossenkov; Kai Tan; Michael D Hogarty; John M Maris; Chi V Dang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-08       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.